Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer data have been reported by B. Sherrill and co-authors
October 9th, 2008
According to recent research from the United States, "The addition of lapatinib (Tykerb/Tyverb) to capecitabine ( Xeloda) delays disease progression more effectively than capecitabine monotherapy in women with previously treated HER2+ metastatic breast cancer (MBC). The quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWiST) method was used to compare treatments." "The area under survival curves was partitioned into health states: toxicity (TOX), time without symptoms of disease progression or toxicity (TWiST), and relapse period until death or end of follow-up ( REL). Average times spent in each state, weighted by utility, were derived and...
Source: Women's Health Weekly (2008-10-09)
|
